-
China's first global anti-cancer drug, Bai Yueze, ® approved at home
Time of Update: 2021-03-03
Yesterday, Baiji Shenzhou announced that the company's self-developed next-generation BTK inhibitor, Bai Yueze ® (Zebutini Capsules), has been approved by China's State Drug Administration (NMPA) for the treatment of adult suite cell lymphoma (MCL) patients who have received at least one treatment in the past, and adult chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL) who has received at least one treatment in the past.
-
Cuba's "magic drug" to conquer pneumonia key?
Time of Update: 2021-03-03
First, dengue fever began sporadically in central, western and eastern Cuba at the end of 1980, and was officially confirmed in May, with more than 244,000 people infected by the end of October, an increase of 1,100 cases a day at peak times and 180 deaths before and after.
-
The clinical results of phase 3 of the treatment of pneumonia with a new combination of antibiotics in Mercedon came out
Time of Update: 2021-03-03
The results showed that Recarbrio showed statistically non-poor statistical effectiveness in terms of all-cause mortality and clinical response on the 28th day compared to pyracillin/tazobactam (PIP/TAZ) in terms of the main endpoints and secondary endpoints of the study.
-
Johnson and Johnson Darzalex under-skin injections are approved by the European Union
Time of Update: 2021-03-03
COLUMBA is a randomized open-label study that compared the non-shoddy effectiveness of Darzalex SC and Darzalex IV preparations for single-drug therapy in patients who had previously received at least 3 treatment options (including protease inhibitors (PI), immunomodulation agents (IMiD)) or MM patients who were difficult to treat both PI and IMiD.
-
China's independent research and development of 13-price pneumonia combined vaccine the first batch of products were approved for market
Time of Update: 2021-03-03
subsidiary Yuxi Watson Biotechnology Co., Ltd. produced the first batch of 13-price pneumococcal polysaccharide combination vaccine (hereinafter referred to as "13-price pneumonia combined vaccine"), has been issued by the State Drug Administration "Biological Products Approval Certificate", which marks the product has been officially listed for sale.
-
Treatment of rosacea The FDA approved the first local therapy for minotin
Time of Update: 2021-03-03
, Menlo Therapeutics announced that the U.S. FDA has approved the development of its wholly-owned subsidiary, Foamix Pharmaceuticals, to list Zilxi (1.5% minocyline, FMX103) for the treatment of adult patients with rosacea.
-
Fexuprazaniii is superior to Esomerazole
Time of Update: 2021-03-03
South Korea's Daewoong Pharmaceutical Company recently released the first phase III clinical data of the new gastroesophedic reflow drug fexuprazan at Digestive Disease Week 2020 (DDW), confirming that fexuprazan has significant effects and good safety in inhibiting gastric acid secretion.
-
JESINDA: Two-wheel drive mode to build a new anti-cancer drug pipeline
Time of Update: 2021-03-03
With 24 years of experience in biological research and new drug development, Dr. Wang Shaoxuan, Vice President of the Company, has led and participated in research and development projects for new drugs in oncology, neuroimmune and regenerative medicine, many of which have entered clinical trials and involved in the development of IDH1/2 inhibitors approved for market in the United States.
-
FDA Emergency Channel approves the launch of a new coronavirus nucleic acid testing kit
Time of Update: 2021-03-03
QuantiVirusTM's new coronavirus nucleic acid testing kit uses the company's own molecular diagnostic patented technology to quickly and accurately detect each known SARS-Cov-2 strain.
-
Cancer-induced bone softening new drug Crysvita applied
Time of Update: 2021-03-03
Ultragenyx Pharmaceuticals and partner Kyowa Kirin recently jointly announced that they have submitted a Crysvita (burosumab) Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the treatment of FGF23-related hypothyroidism associated with phosphate urinary folioma (tumor-induced osteoma, TIO).
-
Roche Tecentriq and Avastin first-line treatment is significant
Time of Update: 2021-03-03
IMbrave150 is an open-label, multi-center, randomized Phase III study conducted in patients with non-excisive, localized late stage or metastasis HCC who had not previously received systematic treatment to investigate the efficacy and safety of Tecentriq's combined treatment with Avastin's standard care drug, the multi-kinase inhibitor sorafenib.
-
The first Russian PD-1 original inhibitor was approved
Time of Update: 2021-03-03
The registration of Russia's first original PD-1 inhibitor is an important stage in the development of immuno-oncology and the treatment of patients with malignant tumors," said Dmitry Morozov, CEO of BIOCAD.
-
Regenerative meta "stone man disease" new drug Phase 2 clinical success
Time of Update: 2021-03-03
The regenerative metagaretosmab is able to be combined with downstream targets of the ACVR1 gene-coded protein to prevent abnormal bone growth; blueprint Medicine has developed a BLU-782 that directly targets mutations in ACVR1 to inhibit abnormal protein activity; and Clementia's therapy is the fastest progressing, completing Phase 3 clinical patient registration in August this year and is expected to be test results and approved for market approval in 2020.
-
The initial clinical results of Mirati combination therapy were positive
Time of Update: 2021-03-03
, Mirati Therapeutics published preliminary clinical data on its use in the study of protein kinase inhibitor sitravatinib in association with the anti-PD-1 antibody nivolumab to treat patients with advanced renal transparent cell carcinoma (aCCRCC) in Phase 1/2 clinical trials.
-
Proteomics studies have helped identify potential drugs against SARS-CoV-2
Time of Update: 2021-03-03
researchers at the University of California have been studying proteins used by SARS-CoV-2 virus to bind to lung proteins and have identified a variety of drugs that could be useful for treating COVID-19 patients.
-
Novartis' new adaptation to strong and straight spina blinitis has been approved by the NMPA
Time of Update: 2021-03-03
Skuchiyu monoantigen is one of the first clinically urgent overseas new drugs in China and was approved by NMPA in March 2019 to treat moderate to severe plaque-like psoriasis in adult patients with systemic treatment or phototherapy signs, and was officially listed in China in May of the same year.
-
AbbVie Skyrizi head-to-head Phase III study beats Novaral Cosentyx
Time of Update: 2021-03-03
This multi-center, randomized, open-label, efficacy evaluator-blind, positive drug-controlled study was conducted in adult patients with moderate to severe plaque psoriasis suitable for systematic treatment, comparing the safety and effectiveness of Skyrizi and Cosentyx.
-
Lynparza was given priority in the United States
Time of Update: 2021-03-03
MSD announced that it had successfully granted Lynparza (olaparib) a new application for a new drug and that it had been given priority review in combination with Genentech for advanced ovarian cancer.
-
Russia has developed a new crown vaccine for nasal drips
Time of Update: 2021-03-03
Maksutov, director of the "Vector" National Center for Virology and Biotechnology of the Russian Federation's Consumer Protection and Public Interest Supervision Agency, said the center had developed a nasal drip-in new coronavirus vaccine on May 21.
-
Incyte Jak1 inhibitors were not confirmed in GVHD trials
Time of Update: 2021-03-03
Incyte announced the latest results from its Phase II study, which evaluated Itacitinib (formerly incb039110) in a combined treatment with corticosteroids to treat patients who had not received acute graft anti-host disease (gvhd).
